Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSPO | P30536 | 8/20 | 0.65 |
| ▸ | ALB | P02768 | 1/20 | 0.65 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.60 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2757554 | 0.84 | TSPO (0.86) | TSPOALBOPRK1 | |
| SCHEMBL29478041 | 0.84 | TSPO (0.86) | TSPOALBOPRK1 | |
| SCHEMBL16569003 | 0.79 | TSPO (1.00) | TSPOALBOPRK1 | |
| SCHEMBL17689605 | 0.76 | TSPO (0.78) | TSPOALBOPRK1 | |
| SCHEMBL29573015 | 0.76 | TSPO (0.78) | TSPOALBOPRK1 | |
| SCHEMBL18068951 | 0.76 | TSPO (0.83) | TSPOALBOPRK1 | |
| SCHEMBL12405739 | 0.75 | TSPO (0.78) | TSPOALBOPRK1 | |
| SCHEMBL29377466 | 0.75 | TSPO (1.00) | TSPOALBOPRK1 | |
| SCHEMBL2757551 | 0.75 | TSPO (1.00) | TSPOALBOPRK1 | |
| SCHEMBL2757548 | 0.75 | TSPO (1.00) | TSPOALBOPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2408451-A2 | RADIOLABELLED PYRIDINYL DERIVATIVES FOR IN-VIVO IMAGING | GE Healthcare UK Limited (GB) | 2012-01-25 | — | — | EP | disclosed |
| US-20120003154-A1 | ARYLOXYANILIDE DERIVATIVES | GE HEALTHCARE LIMITED (GB) | 2012-01-05 | — | — | US | disclosed |
| WO-2010106166-A2 | ARYLOXYANILIDE DERIVATIVES | GE HEALTHCARE LIMITED (GB) | 2010-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120003154-A1 | ARYLOXYANILIDE DERIVATIVES | GABBR1, GABRA4, CNR1 | TSPO 43/4885ALB 4666/4885OPRK1 57/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.